<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="pmc-domain-id">440</journal-id><journal-id journal-id-type="pmc-domain">plosone</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>PLOS</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431355</article-id><article-id pub-id-type="pmcid-ver">PMC12431355.1</article-id><article-id pub-id-type="pmcaid">12431355</article-id><article-id pub-id-type="pmcaiid">12431355</article-id><article-id pub-id-type="pmid">40938895</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0328881</article-id><article-id pub-id-type="publisher-id">PONE-D-24-40803</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Carcinoma</subject><subj-group><subject>Thyroid Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Endocrine Tumors</subject><subj-group><subject>Thyroid Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Lung and Intrathoracic Tumors</subject><subj-group><subject>Thymic Tumors</subject><subj-group><subject>Thyroid Carcinoma</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Processes</subject><subj-group><subject>Cell Death</subject><subj-group><subject>Apoptosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and Neoplasms</subject><subj-group><subject>Breast Tumors</subject><subj-group><subject>Breast Cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Molecular Biology</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Gene Expression and Vector Techniques</subject><subj-group><subject>Hyperexpression Techniques</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Molecular Biology Techniques</subject><subj-group><subject>Molecular Biology Assays and Analysis Techniques</subject><subj-group><subject>Gene Expression and Vector Techniques</subject><subj-group><subject>Hyperexpression Techniques</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Prognosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject><subj-group><subject>Cancer Risk Factors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Risk Factors</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>ETS2 targets ZMYND11 to inhibit thyroid cancer progression via the mTOR signaling pathway</article-title><alt-title alt-title-type="running-head">ETS2-ZMYND11 regulates THCA via mTOR pathway</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Shu</surname><given-names initials="T">Taipengfei</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0000-3095-1294</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="X">Xinhua</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="C">Chengqun</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="C">Chaofeng</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shen</surname><given-names initials="C">Chao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="Y">Yujie</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="J">Jie</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="L">Liangxing</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="T">Ting</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="W">Wen</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="L">Liming</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yan</surname><given-names initials="Y">Yan</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="T">Tao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ji</surname><given-names initials="N">Ning</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="J">Jun</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Xie</surname><given-names initials="X">Xiangyu</given-names></name><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhu</surname><given-names initials="P">Ping</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="aff009" ref-type="aff">
<sup>9</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Endocrinology, Huai&#8217;an Clinical Medical College of Jiangsu University &amp; Huai&#8217;an Hospital of Huai&#8217;an City &amp; Huai&#8217;an Cancer Hospital &amp;The Affiliated Huai&#8217;an Hospital of Jiangsu College Of Nursing, Huai&#8217;an City, Jiangsu Province, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, School of Medicine, Jiangsu university, Zhenjiang, Jiangsu, P.R. China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Central Laboratory, Huai'an Clinical Medical College of Jiangsu University &amp; Huai'an Hospital of Huai'an City &amp; Huai'an Cancer Hospital &amp;The Affiliated Huai'an Hospital of Jiangsu College Of Nursing, Huai'an City, Jiangsu Province, China</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Neurology, Huai&#8217;an Clinical Medical College of Jiangsu University &amp; Huai&#8217;an Hospital of Huai&#8217;an City &amp; Huai&#8217;an Cancer Hospital &amp;The Affiliated Huai&#8217;an Hospital of Jiangsu College Of Nursing, Huai&#8217;an City, Jiangsu Province, China</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of cardiovascular medicine, Huai&#8217;an Clinical Medical College of Jiangsu University &amp; Huai&#8217;an Hospital of Huai&#8217;an City &amp; Huai&#8217;an Cancer Hospital &amp;The Affiliated Huai&#8217;an Hospital of Jiangsu College Of Nursing, Huai&#8217;an City, Jiangsu Province, China</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Clinical Laboratory, Huai&#8217;an Clinical Medical College of Jiangsu University &amp; Huai&#8217;an Hospital of Huai&#8217;an City &amp; Huai&#8217;an Cancer Hospital &amp;The Affiliated Huai&#8217;an Hospital of Jiangsu College of Nursing, Huai&#8217;an, China</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Endoscopy Center, Minhang Hospital, Fudan University, Shanghai, China,</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of General Surgery, Huai&#8217;an Clinical Medical College of Jiangsu University &amp; Huai&#8217;an Hospital of Huai&#8217;an City &amp; Huai&#8217;an Cancer Hospital &amp; The Affiliated Huai&#8217;an Hospital of Jiangsu College of Nursing, Huai&#8217;an City, Jiangsu Province, China,</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Endocrinology, The Affiliated Chuzhou Hospital of Traditional Chinese Medicine of Jiangsu College of Nursing, Huai&#8217;an, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Li</surname><given-names initials="Z">Zhanzhan</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Xiangya Hospital Central South University, CHINA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>835879050@qq.com</email> (PZ); <email>13511518186@163.com</email> (XX)</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496058</issue-id><elocation-id>e0328881</elocation-id><history><date date-type="received"><day>9</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>8</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Shu et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Shu et al</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pone.0328881.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="pone.0328881.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Despite advancements in thyroid cancer (THCA) treatment, the prognosis for advanced cases remains poor. Cellular senescence is crucial in tumor progression, with <italic toggle="yes">ETS2</italic> emerging as a key regulator. However, the role of <italic toggle="yes">ETS2</italic> and its interaction with <italic toggle="yes">ZMYND11</italic> in THCA is unclear.</p></sec><sec id="sec002"><title>Methods</title><p>Differentially expressed genes (DEGs) connected with cellular senescence were determined from The Cancer Genome Atlas (TCGA)-THCA dataset. Functional analysis, prognostic risk model, and nomogram were then performed to identify <italic toggle="yes">ETS2</italic> as a hub gene. The roles of <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> were explored using Western blotting (WB), co-immunoprecipitation (Co-IP), and quantitative real-time polymerase chain reaction (qRT-PCR). Effects of <italic toggle="yes">ETS2</italic> overexpression and knockdown of <italic toggle="yes">ZMYND11</italic> on apoptosis, cell proliferation, epithelial-mesenchymal transition (EMT), and mTOR signaling were evaluated. <italic toggle="yes">In vivo</italic>, a xenograft model was established using Cal-62 cells with or without <italic toggle="yes">ETS2</italic> overexpression to assess tumor growth and protein expression.</p></sec><sec id="sec003"><title>Results</title><p><italic toggle="yes">ETS2</italic> was notably downregulated in THCA, and its low expression was connected to adverse prognosis. <italic toggle="yes">ETS2</italic> overexpression inhibited THCA cell invasion, migration, proliferation, and induced apoptosis. <italic toggle="yes">ETS2</italic> also regulated the expression of EMT markers, indicating its role in inhibiting THCA progression. Co-IP analysis showed that ETS2 interacted with ZMYND11. Knockdown of <italic toggle="yes">ZMYND11</italic> attenuated the inhibitory effect of <italic toggle="yes">ETS2</italic> on THCA cell behavior and mTOR pathway regulation. <italic toggle="yes">In vivo</italic>, <italic toggle="yes">ETS2</italic> overexpression reduced tumor growth and increased <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> expression in xenograft tumors.</p></sec><sec id="sec004"><title>Conclusion</title><p>This study identified the cellular senescence gene <italic toggle="yes">ETS2</italic> as a tumor suppressor in THCA, which interacts with <italic toggle="yes">ZMYND11</italic> to regulate THCA tumor progression through the mTOR pathway, thereby inhibiting cell senescence. Targeting the <italic toggle="yes">ETS2</italic>-<italic toggle="yes">ZMYND1</italic> axis may provide new therapeutic strategies and prognostic biomarkers for THCA.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Science and Education Integration Research Development Foundation of Jiangsu College of Nursing</institution></funding-source><award-id>024SH121003</award-id><principal-award-recipient><name name-style="western"><surname>Shu</surname><given-names>Taipengfei</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution>Jiangsu Provincial Health Commission Research Project</institution></funding-source><award-id>Z2024044</award-id><principal-award-recipient><name name-style="western"><surname>Shu</surname><given-names>Taipengfei</given-names></name></principal-award-recipient></award-group><funding-statement>This study is supported by The Science and Education Integration Research Development Foundation of Jiangsu College of Nursing (No. SH202410250209) and Jiangsu Provincial Health Commission Research Project (Z2024044).</funding-statement></funding-group><counts><fig-count count="13"/><table-count count="2"/><page-count count="26"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec041" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec041" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>As a potentially lethal malignant tumor, thyroid cancer (THCA) grows rapidly [<xref rid="pone.0328881.ref001" ref-type="bibr">1</xref>]. It is highly invasive, especially in the undifferentiated form, with a negative prognosis and low survival rate, presenting a serious threat to the health of patients. Papillary thyroid cancer accounts for 80&#8211;90% of occurrences of thyroid cancer, making it the most prevalent kind of all types [<xref rid="pone.0328881.ref002" ref-type="bibr">2</xref>]. Since 2000, the occurrence of THCA has increased by 20% every year, and by 2022 it has become the third most prevalent cancer in China [<xref rid="pone.0328881.ref003" ref-type="bibr">3</xref>]. THCA is more prevalent in females than in males and is specifically prevalent in young and elderly people [<xref rid="pone.0328881.ref004" ref-type="bibr">4</xref>]. Current treatment strategies for thyroid cancer include radioactive iodine therapy, surgical intervention, targeted therapy, and immunotherapy [<xref rid="pone.0328881.ref005" ref-type="bibr">5</xref>]. Cellular senescence refers to a stable state of proliferation arrest in cells after irreversible damage or stress. Recently, the function of cell senescence in THCA has received increasing attention. The senescence-associated secretory phenotype (SASP) may serve a promoting function in tumor growth and metastasis by promoting angiogenesis, tumor cell proliferation, and immune escape [<xref rid="pone.0328881.ref006" ref-type="bibr">6</xref>]. Studies have shown that senescence-related characteristics may become important biomarkers for estimating the prognosis of THCA and guiding immunotherapy, such as <italic toggle="yes">DOCK6</italic> and <italic toggle="yes">ADAMTSL4</italic> [<xref rid="pone.0328881.ref007" ref-type="bibr">7</xref>]. These findings offer fresh perspectives on the diagnosis and management of thyroid cancer and emphasize the significance of aging mechanisms in cancer research.</p><p><italic toggle="yes">ETS2</italic> is a transcription factor closely related to cell senescence and belongs to the ETS family. It is essential for many biological activities, comprising cell proliferation, apoptosis, differentiation, development, and tumorigenesis [<xref rid="pone.0328881.ref008" ref-type="bibr">8</xref>]. As one of the cell senescence-related genes, <italic toggle="yes">ETS2</italic> is involved in regulating multiple key cell signaling pathways in tumors, such as the JAK/STAT, RAS/MAPK, and PI3K/AKT pathways, which perform an essential function in the occurrence and progression of cancer. In some cancer types, <italic toggle="yes">ETS2</italic> exhibits oncogenic properties. For example, overexpression of <italic toggle="yes">ETS2</italic> is intimately related to tumor progression, invasion, and metastasis in breast cancer, colorectal cancer, and prostate cancer [<xref rid="pone.0328881.ref009" ref-type="bibr">9</xref>]. Research findings have also indicated that <italic toggle="yes">ETS2</italic> may encourage the development of cancer by activating genes like Myc and Cyclin D1 that are involved in cell survival and proliferation [<xref rid="pone.0328881.ref010" ref-type="bibr">10</xref>]. Additionally, <italic toggle="yes">ETS2</italic> has the potential to act as a specific marker for the early detection of acute myocardial infarction (AMI), and its early detection capability provides a new opportunity for timely intervention in cardiovascular diseases [<xref rid="pone.0328881.ref011" ref-type="bibr">11</xref>]. Cellular senescence-related gene markers have also been shown to reliably predict patient prognosis and immunotherapy efficacy, especially in immunotherapy for hepatocellular carcinoma, in which <italic toggle="yes">ETS2</italic> is a key research subject.</p><p><italic toggle="yes">ZMYND11</italic>, also known as <italic toggle="yes">BS69</italic>, is a zinc finger domain-containing protein belonging to the MYND domain protein family. <italic toggle="yes">ZMYND11</italic> can function as a co-repressor of transcription, interacting with promoter regions of specific genes and inhibiting their transcription [<xref rid="pone.0328881.ref012" ref-type="bibr">12</xref>]. Previous studies have indicated interactions between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic>. Research by Plotnik JP et al. demonstrated that <italic toggle="yes">ETS1</italic> and <italic toggle="yes">ETS2</italic> have opposing regulatory roles in the gene expression program for cell migration, with the function of ETS2 being specifically modulated by the co-repressor <italic toggle="yes">ZMYND11</italic>, which determines its oncogenic or tumor-suppressive roles in different cellular contexts [<xref rid="pone.0328881.ref013" ref-type="bibr">13</xref>]. Similarly, Wei G et al. found that <italic toggle="yes">BS69</italic> acts as a co-repressor interacting with <italic toggle="yes">ETS2</italic>, and phosphorylation of <italic toggle="yes">ETS2</italic> reduces this interaction, potentially shifting its function from a repressor to an activator [<xref rid="pone.0328881.ref014" ref-type="bibr">14</xref>]. Therefore, this research aims to investigate the roles and mechanistic pathways of <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in THCA, thereby providing new directions for the treatment of THCA.</p><p>Despite advances in THCA treatment, including radioiodine therapy, surgery, targeted therapy, and immunotherapy, the prognosis of advanced cases remains poor. Recent studies have highlighted key factors in the progression of THCA, like <italic toggle="yes">ETS2</italic>, a transcriptional regulator implicated in tumor development and metastasis in various cancers [<xref rid="pone.0328881.ref015" ref-type="bibr">15</xref>]. <italic toggle="yes">ETS2</italic> is known to regulate key cellular processes by modulating multiple signaling pathways. This research attempts to clarify the function of <italic toggle="yes">ETS2</italic> in THCA by exploring its interaction with <italic toggle="yes">ZMYND11</italic>. By investigating their effects on cell proliferation, epithelial-mesenchymal transition (EMT), apoptosis, and the mTOR pathway, this investigation aims to find possible therapeutic targets and biomarkers to ultimately improve the prognosis and therapeutic strategies of THCA.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Analysis of differentially expressed genes related to cellular senescence in THCA</title><p>Samples connected to THCA were acquired from The Cancer Genome Atlas (TCGA) database via the Sangerbox tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://vip.sangerbox.com/home.html" ext-link-type="uri">http://vip.sangerbox.com/home.html</ext-link>) for this research. The dataset included 512 THCA tumor samples and 59 adjacent normal samples from TCGA. The selection of cutoff values for DEGs was based on commonly accepted thresholds in bioinformatics studies to balance the sensitivity and specificity of gene identification. DEGs were characterized based on a log<sub>2</sub> fold change (FC) threshold of &lt;&#8722;1 for downregulated genes and &gt;1 for upregulated genes, as this level of change is generally considered significant in gene expression studies. Additionally, a P-value threshold of &lt;0.05 was applied to ensure the statistical robustness of the identified DEGs, reducing the likelihood of false positives. These criteria were selected to provide a reliable and interpretable set of DEGs for subsequent analyses. To investigate the relationship between DEGs and cellular senescence, 278 genes connected with cell senescence were acquired from the CellAge database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://genomics.senescence.info/cells/" ext-link-type="uri">https://genomics.senescence.info/cells/</ext-link>). Intersection analysis of cell senescence-related genes and DEGs was performed using the Venn online graph tool (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bioinformatics.psb.ugent.be/webtools/Venn/" ext-link-type="uri">https://bioinformatics.psb.ugent.be/webtools/Venn/</ext-link>) to identify overlapping genes.</p></sec><sec id="sec008"><title>Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis</title><p>The enrichment analysis for cellular senescence-associated genes in THCA, focusing on GO and KEGG pathways, was conducted via the Xiantao Academic platform (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.xiantao.love/products" ext-link-type="uri">https://www.xiantao.love/products</ext-link>). This analysis sought to highlight key biological processes, cellular structures, molecular functions, and signaling pathways. A <italic toggle="yes">P</italic>-value&#8201;&lt;&#8201;0.05 was applied as the significance threshold for all results obtained from the enrichment analysis.</p></sec><sec id="sec009"><title>Univariate Cox regression analysis and protein-protein interaction (PPI) analysis</title><p>To evaluate the prognostic significance of cellular senescence-related genes in THCA, we employed univariate Cox regression analysis. Cox regression is based on the proportional hazards assumption, which posits that the hazard ratio for the effect of a covariate is constant over time. To ensure the validity of this assumption in our analysis, we evaluated the proportional hazards through diagnostic tests. 95% confidence intervals (CIs) and Hazard ratios (HRs) were measured to determine genes significantly connected to overall survival. <italic toggle="yes">P</italic>-values&#8201;&lt;&#8201;0.05 suggested that the findings were statistically significant. In addition, with the Search tool for the retrieval of interacting genes/proteins (STRING; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://string-db.org/" ext-link-type="uri">https://string-db.org/</ext-link>) database, PPI networks were built, and Cytoscape software (version 3.10.2) was utilized to display the results.</p></sec><sec id="sec010"><title>Prognostic feature construction and risk model evaluation using least absolute shrinkage and selection operator (LASSO) regression</title><p>The creation of prognostic characteristics used the LASSO regression analysis in R, utilizing the &#8220;glmnet&#8221; package. LASSO regression assumes that there is sparsity among the features, meaning that only a small subset of the variables were truly associated with the outcome, while others have coefficients shrunk to zero. This assumption ensures that the model can effectively handle high-dimensional data and prevent overfitting. LASSO regression was employed to identify relevant prognostic features from a set of nine prognostic genes, with optimal gene selection determined through 10-fold cross-validation. Based on this analysis, the following algorithm was used to determine a risk score for every patient: Riskscore=(0.2922)*<italic toggle="yes">MMP9</italic>+(0.7243)*<italic toggle="yes">SRSF1</italic>+(&#8722;0.4812)*<italic toggle="yes">FASTK</italic>+(&#8722;0.1894)*<italic toggle="yes">CBX7</italic>+(&#8722;1.0796)*<italic toggle="yes">ETS2</italic>. Based on the median value of the computed risk scores, groups of patients then categorized as high-risk and low-risk were formed. Kaplan-Meier survival curves were generated to compare survival differences between these groups utilizing the &#8220;survival&#8221; package in R. The &#8220;timeROC&#8221; R package was utilized to create receiver operating characteristic (ROC) curves, which evaluated the predictive capacity of the risk model. Throughout the studies, statistical significance was measured with a threshold of <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></sec><sec id="sec011"><title>Construction of prognostic nomogram for THCA</title><p>Five key signature genes were identified from the prognostic risk model. To evaluate the relevance of the prognosis of these selected genes and clinical variables (comprising age, gender, pN stage, pT stage, and pM stage), univariate and multivariate Cox regression analyses were performed via the &#8220;survival&#8221; R package. To find independent prognostic factors, variables having a <italic toggle="yes">P</italic>-value&#8201;&lt;&#8201;0.05 in the univariate analysis were added to the multivariate model. Subsequently, the &#8220;rms&#8221; R program was employed to create a nomogram that predicted the overall survival rates at 1, 3, and 5 years. Calibration curves were generated to evaluate the concordance between observed and predicted survival rates, enabling the identification of hub genes in this study.</p></sec><sec id="sec012"><title>Expression analysis and survival analysis of ETS2 in pan-cancer</title><p>To validate the biological characteristics of the hub gene, we initially conducted a pan-cancer expression analysis, focusing particularly on THCA tumor tissues, utilizing the Gene Expression Profiling Interactive Analysis (GEPIA) database (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://gepia.cancer-pku.cn/" ext-link-type="uri">http://gepia.cancer-pku.cn/</ext-link>). This platform provides comprehensive gene expression profiling among many forms of cancer, allowing for the assessment of differential expression patterns. Subsequently, Kaplan-Meier survival analyses were performed to assess the impact of differential expression of these key genes on progression-free survival (PFS) and disease-free survival (DFS) in THCA patients, determining the prognostic significance associated with their expression levels.</p></sec><sec id="sec013"><title>Immunohistochemical (IHC) analysis of ETS2 in THCA tissues</title><p>Thyroid tissue samples that were formalin-fixed, paraffin-embedded (FFPE) were provided by the Shanghai Minhang Central Hospital on 28/06/2024 and authorized by the Institutional Ethics Committee (2024-Approval-015&#8211;112). IHC staining was performed using an IHC kit (BOSTER, China). After being deparaffinized and rehydrated, the tissue slices were incubated at 95&#176;C for ten minutes in Tris-EDTA buffer (Solarbio, China) for antigen retrieval. An incubation period of 10 minutes at room temperature inhibited endogenous peroxidase activity. After blocking the sections with 5% bovine serum albumin (BSA) for 30 minutes at room temperature, they were treated with an anti-ETS2 antibody (1:100, Abcam, China) overnight at 4&#176;C. Following incubation, the slices were subjected to a biotin-labeled goat anti-mouse IgG secondary antibody and visualized using a DAB substrate kit (ZSGB, Beijing, China). subsequently, 1% hematoxylin was applied to the slices for counterstaining and imaged using a Leica DMI3000B microscope.</p></sec><sec id="sec014"><title>Ethics approval and consent to participate</title><p>Our study was conducted with the approval of the Ethics Committee of Shanghai Minhang Central Hospital, and informed consent for the relevant research was obtained(2024-approval-015-112).</p><p>All animal experiments were performed in accordance with the guidelines for the care and use of laboratory animals and were approved by the Animal Ethics Committee of Hefei National Comprehensive Science Center Institute of Health (Approval No. IHM-API-2025-007). All efforts were made to minimize animal suffering and reduce the number of animals used.</p></sec><sec id="sec015"><title>Cell culture conditions</title><p>THCA cell lines (Cal-62, TPC-1, and BC-PAP) and normal thyroid epithelial cells (Nthy-ori 3-1) were acquired from Procell (Wuhan, China). Every cell was cultured in RPMI-1640 medium (Gibco, Shanghai, China), which was enhanced with 1% penicillin-streptomycin and 10% fetal bovine serum (FBS). At 37&#176;C, the cells were maintained in a humidified atmosphere with 5% CO<sub>2</sub>.</p></sec><sec id="sec016"><title>Cell transfection</title><p>In 24-well plates, Cal-62 and TPC-1 cells were seeded at a density of 2&#8201;&#215;&#8201;10<sup>4</sup> cells per well and grown for a whole night in a complete growth medium to reach approximately 70&#8211;80% confluence. By the manufacturer&#8217;s instructions, Lipofectamine 2000 (BioSharp, China) was employed for transfections. ETS2 overexpression plasmids and <italic toggle="yes">ZMYND11</italic> knockdown plasmids, along with their respective negative controls (over-NC, si-NC), were introduced into the cells. The sequence used for the <italic toggle="yes">ZMYND11</italic> knockdown was GAAGGGAAATACCGAAGTTAT. 48 hours after transfection, cells were collected for further analyses. All transfection procedures followed standardized protocols to ensure reproducibility and accuracy.</p></sec><sec id="sec017"><title>Quantitative real-time polymerase chain reaction (qRT-PCR)</title><p>TRIzol reagent (Thermo Fisher Scientific, Shanghai, China) was applied to extract total RNA from Cal-62 and TPC-1 cells by the manufacturer&#8217;s instructions. The quantity and quality of RNA were assessed utilizing a NanoDrop spectrophotometer (Thermo Fisher Scientific, Shanghai, China). Subsequently, cDNA synthesis was performed via the PrimeScript RT Kit (Takara, Shiga, Japan) with 1 &#956;g of total RNA as the template. To analyze the gene expression levels, qRT-PCR was conducted by the StepOnePlus Real-Time PCR System (Applied Biosystems, Shanghai, China). SYBR Green PCR Master Mix (Applied Biosystems, Shanghai, China) was utilized for qRT-PCR reactions. Gene expression analysis was conducted utilizing the 2<sup>-&#916;&#916;CT</sup> method, with &#946;-actin serving as the internal control for normalization. The primer sequences employed in qRT-PCR are listed in <xref rid="pone.0328881.t002" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="pone.0328881.t002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.t002</object-id><label>Table 2</label><caption><title>Primer sequences for qRT-PCR.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0328881.t002g" position="float" orientation="portrait" xlink:href="pone.0328881.t002.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Target</th><th align="left" rowspan="1" colspan="1">Direction</th><th align="left" rowspan="1" colspan="1">Sequence (5&#8217;-3&#8217;)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ETS2</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">GGCCCGGTTTCTACAGGAAG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ETS2</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">CTTTGGAATTCCGCAGCGAC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZMYND11</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">ACAAAAAGACGACAGGCGGA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZMYND11</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">ACGGGTGGTCTCTTTAGGGT</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Bax</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">CTGCAGAGGATGATTGCCG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Bax</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TGCCACTCGGAAAAAGACCT</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Bcl-2</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">TCCCTCGCTGCACAAATACTC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Bcl-2</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">ACGACCCGATGGCCATAGA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Caspase-3</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">AGGGGTCATTTATGGGACA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Caspase-3</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TACACGGGATCTGTTTCTTTG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Caspase-9</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">AGGCCCCATATGATCGAGGA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Caspase-9</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TCGACAACTTTGCTGCTTGC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">E-cadherin</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">ACATACACTCTCTTCTCTC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">E-cadherin</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">GTCATTCTGATCGGTTAC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N-cadherin</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">GGGTGGAGGAGAAGAAGACCAG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">N-cadherin</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">GGCATCAGGCTCCACAGT</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Vimentin</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">AACCTGAGGGAAACTAAT</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Vimentin</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TTGATAACCTGTCCATCT</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZEB1</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">GAAAGTGTTACAGATGCAG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZEB1</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TTCCTTTCCTGTGTCATC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZEB2</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">ATGAAGCAGCCGATCATGGCG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">ZEB2</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">CACACATCTTGGAGCAAAAGCATG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Snail</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">GAAAAGGGACTGTGAGTA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Snail</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">GAATAGTTCTGGGAGACA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Slug</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">CTGGTCAAGAAGCATTTC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Slug</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">GGGGAAATAATCACTGTATG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">S6K1.</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">CACATAACCTGTGGTCTGTTGCTG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">S6K1.</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">AGATGCAAAGCGAACTTGGGA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NF-&#954;B1</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">GCCTCCACAAGGCAGCAAATA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">NF-&#954;B1</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">CACCACTGGTCAGAGACTCGGTAA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">COX2</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">AAGTCC CTGAGCATCTACG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">COX2</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">TTCCTA CACCAGCAACC</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">4EBP1</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">TATGACCGGAAATTCCTGATG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">4EBP1</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">CCATCTCAAACTGTGACTCTTCA</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#946;-actin</italic>
</td><td align="left" rowspan="1" colspan="1">Forward</td><td align="left" rowspan="1" colspan="1">TCCTTCCTGGGCATGGAG</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">&#946;-actin</italic>
</td><td align="left" rowspan="1" colspan="1">Reverse</td><td align="left" rowspan="1" colspan="1">AGGAGGGGCAATGATCTT</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec018"><title>Western blotting (WB)</title><p>By applying RIPA lysis buffer that has been enhanced with inhibitors (Thermo Fisher Scientific, Shanghai, China) of proteases and phosphatases, protein lysates of Cal-62 and TPC-1 cells were generated. With a BCA protein assay kit (Beyotime, Jiangsu, China), the protein content was ascertained. Proteins in equal quantities were separated by SDS-PAGE and then put onto a PVDF membrane (BSA, Beyotime, Jiangsu, China). All antibodies were purchased from Abcam, Shanghai, China. Primary antibodies were employed to identify the following proteins on the membrane: ETS2, Bax, Caspase-3, Bcl-2, Caspase-9, N-cadherin, E-cadherin, Vimentin, ZEB1, ZEB2, Snail, Slug, ZMYND11, S6K1, NF-&#954;B, COX2, and 4EBP1, with &#946;-actin serving as a loading control. Except for 4EBP1 and &#946;-actin, which were diluted at 1:2000, all other antibodies were diluted at 1:1000. An ECL chemiluminescence detection kit (Beyotime, Jiangsu, China) was applied to observe the protein bands, following incubation with secondary antibodies. A densitometric analysis was executed via the ImageJ software (version 2.0).</p></sec><sec id="sec019"><title>Cell Counting Kit-8 (CCK-8) assay</title><p>The CCK-8 test (CK04, Dojindo, China) was employed to assess the activity of cell proliferation. After treatment, Cal-62 and TPC-1 cells were cultured at a concentration of 5&#8201;&#215;&#8201;10<sup>3</sup> cells per well in 96-well plates. Ten microliters of CCK-8 reagent were supplied to every well at the predetermined intervals of time (0, 24, 48, 72, and 96 hours). The plates were then cultured for 4 hours at 5% CO<sub>2</sub> at 37&#176;C in a cell culture incubator. Following the incubation period, a Thermo Fisher Scientific microplate reader (Shanghai, China) was employed to determine the 450&#8201;nm absorbance.</p></sec><sec id="sec020"><title>Transwell migration and invasion assay</title><p>Cells were harvested and resuspended at a concentration of 5&#8201;&#215;&#8201;10<sup>4</sup> cells/well 24 hours after the experiment. These cells were then added into the top chamber of a Transwell insert (24-well format). To replicate the extracellular matrix barrier, Matrigel (Corning) was pre-coated on the top chamber for the invasion experiment. The lower chamber was supplemented with a complete medium to act as a chemoattractant. Following 48 hours of incubation at 37&#176;C, cells remaining in the upper chamber, which did not migrate or invade, were carefully eliminated with a cotton swab. situated beneath the membrane were adhered to utilizing 4% paraformaldehyde and stained with DAPI to visualize the nuclei. Migrated or invaded cells were then visualized and quantified under a fluorescence microscope. Images were subsequently captured for documentation.</p></sec><sec id="sec021"><title>Flow cytometry</title><p>To evaluate cell apoptosis in TPC-1 and Cal-62 cells, flow cytometry analysis was performed in this work. After being plated on 24-well plates at a density of 1&#8201;&#215;&#8201;10<sup>4</sup> cells per well, the Cal-62 and TPC-1 cells were cultured for 24 hours. Following dissociation with trypsin-EDTA and washing with PBS, cells were cultured with 5 &#956;L of PI and 5 &#956;L Annexin V-FITC of solution at ambient temperature for 15 minutes for apoptosis analysis. Subsequently, a flow cytometer (Jiyuan, Guangzhou, China) was used to assess the staining of PI and Annexin V, and FlowJo software was used to analyze the results.</p></sec><sec id="sec022"><title>Co-immunoprecipitation (Co-IP) assays</title><p>Co-IP assays were conducted to validate the relationship between ETS2 and ZMYND11. Plasmids with overexpressed ETS2 or empty vector controls were transfected into Cal-62 and TPC-1 cells. Forty-eight hours post-transfection, protease inhibitor-containing IP lysis solution (Thermo Fisher Scientific, USA) was employed to lyse the cells. The lysates were incubated with an anti-ETS2 antibody for a whole night at 4&#176;C with gentle rotation to allow for immune complex formation. These complexes were then captured using Protein A/G agarose beads (Thermo Fisher Scientific, USA), followed by washing three times with cold lysis buffer to remove non-specifically bound proteins. The bound proteins were dissociated by heating the beads in the SDS-PAGE loading buffer.</p></sec><sec id="sec023"><title>Mouse xenograft model</title><p>Six BALB/c nude mice, aged 4&#8211;5 weeks, were obtained from Vital River Laboratory Animal Technology Co., Ltd. The mice were housed in specific pathogen-free (SPF) conditions with a 12-hour light/dark cycle and were provided with food and water ad libitum. All animal experiments were approved by the Hefei National Comprehensive Science Center Institute of Health (Approval No.: IHM-API-2025&#8211;007) and were conducted in accordance with the guidelines for the care and use of laboratory animals.</p><p>The mice were randomly divided into two groups (n&#8201;=&#8201;3 per group). Cal-62 thyroid cancer cells were transfected with an expression plasmid (over-<italic toggle="yes">ETS2</italic> group) or an empty vector (vector) and suspended in PBS. Each mouse was subcutaneously injected with 1&#8201;&#215;&#8201;10&#8310; cells into the right flank. All mice were euthanized on day 24 after injection. Tumors were carefully excised, photographed, and weighed. The tumor tissues were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned for subsequent IHC analysis of ETS2 and ZMYND 11 expression.</p><p>The IHC experiments were performed as described previously. The antibodies used were anti-ETS2 (1:100, Abcam, China) and anti-ZMYND11 (1:250, Abcam, China). Imaging was conducted using a Leica DMI3000B microscope.</p></sec><sec id="sec024"><title>Statistical analysis</title><p>For statistical analysis of our dataset, the R programming language was employed. Student&#8217;s t-test was utilized to assess intergroup differences and mean values along with their standard deviations (SD) were reported. Tukey&#8217;s post-hoc test was performed in conjunction with analysis of variance (ANOVA) to evaluate differences between several groups. There was a predefined significance level of <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec sec-type="results" id="sec025"><title>Results</title><sec id="sec026"><title>Identification and functional analysis of cellular senescence-related genes in THCA</title><p>This research identified DEGs from the TCGA-THCA dataset. Following criteria based on FC and <italic toggle="yes">P</italic>-value, we detected 3,260 downregulated and 557 upregulated DEGs (<xref rid="pone.0328881.g001" ref-type="fig">Fig 1A</xref>). A topological analysis was conducted further to understand the connection between these DEGs and cellular senescence, revealing 61 overlapping genes (<xref rid="pone.0328881.g001" ref-type="fig">Fig 1B</xref>). After that, GO and KEGG enrichment analyses were employed on these 61 overlapping genes to elucidate their functional roles and contributions to biological processes (<xref rid="pone.0328881.g001" ref-type="fig">Figs 1C</xref>, <xref rid="pone.0328881.g001" ref-type="fig">1D</xref>; detailed results in <xref rid="pone.0328881.t001" ref-type="table">Table 1</xref>). Univariate Cox regression analysis was applied to refine these genes, identifying nine crucial genes associated with prognosis (<xref rid="pone.0328881.g001" ref-type="fig">Fig 1E</xref>). To gain insights into the complex intracellular processes and signaling pathways, a PPI network analysis was performed on the nine prognostic genes (<xref rid="pone.0328881.g001" ref-type="fig">Fig 1F</xref>).</p><table-wrap position="float" id="pone.0328881.t001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.t001</object-id><label>Table 1</label><caption><title>GO and KEGG pathway enrichment analysis of differentially expressed genes in THCA.</title></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="pone.0328881.t001g" position="float" orientation="portrait" xlink:href="pone.0328881.t001.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">ONTOLOGY</th><th align="left" rowspan="1" colspan="1">ID</th><th align="left" rowspan="1" colspan="1">Description</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BP</td><td align="left" rowspan="1" colspan="1">GO:0018105</td><td align="left" rowspan="1" colspan="1">peptidyl-serine phosphorylation</td></tr><tr><td align="left" rowspan="1" colspan="1">BP</td><td align="left" rowspan="1" colspan="1">GO:0018209</td><td align="left" rowspan="1" colspan="1">peptidyl-serine modification</td></tr><tr><td align="left" rowspan="1" colspan="1">BP</td><td align="left" rowspan="1" colspan="1">GO:0043154</td><td align="left" rowspan="1" colspan="1">negative regulation of cysteine-type endopeptidase activity involved in apoptotic process</td></tr><tr><td align="left" rowspan="1" colspan="1">BP</td><td align="left" rowspan="1" colspan="1">GO:0043281</td><td align="left" rowspan="1" colspan="1">regulation of cysteine-type endopeptidase activity involved in apoptotic process</td></tr><tr><td align="left" rowspan="1" colspan="1">BP</td><td align="left" rowspan="1" colspan="1">GO:2000117</td><td align="left" rowspan="1" colspan="1">negative regulation of cysteine-type endopeptidase activity</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">GO:0000790</td><td align="left" rowspan="1" colspan="1">nuclear chromatin</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">GO:0031519</td><td align="left" rowspan="1" colspan="1">PcG protein complex</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">GO:0016580</td><td align="left" rowspan="1" colspan="1">Sin3 complex</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">GO:0000118</td><td align="left" rowspan="1" colspan="1">histone deacetylase complex</td></tr><tr><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">GO:0035102</td><td align="left" rowspan="1" colspan="1">PRC1 complex</td></tr><tr><td align="left" rowspan="1" colspan="1">MF</td><td align="left" rowspan="1" colspan="1">GO:0004674</td><td align="left" rowspan="1" colspan="1">protein serine/threonine kinase activity</td></tr><tr><td align="left" rowspan="1" colspan="1">MF</td><td align="left" rowspan="1" colspan="1">GO:0001227</td><td align="left" rowspan="1" colspan="1">DNA-binding transcription repressor activity, RNA polymerase II-specific</td></tr><tr><td align="left" rowspan="1" colspan="1">MF</td><td align="left" rowspan="1" colspan="1">GO:0030291</td><td align="left" rowspan="1" colspan="1">protein serine/threonine kinase inhibitor activity</td></tr><tr><td align="left" rowspan="1" colspan="1">MF</td><td align="left" rowspan="1" colspan="1">GO:0033613</td><td align="left" rowspan="1" colspan="1">activating transcription factor binding</td></tr><tr><td align="left" rowspan="1" colspan="1">MF</td><td align="left" rowspan="1" colspan="1">GO:0016538</td><td align="left" rowspan="1" colspan="1">cyclin-dependent protein serine/threonine kinase regulator activity</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05219</td><td align="left" rowspan="1" colspan="1">Bladder cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa01522</td><td align="left" rowspan="1" colspan="1">Endocrine resistance</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05161</td><td align="left" rowspan="1" colspan="1">Hepatitis B</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa04068</td><td align="left" rowspan="1" colspan="1">FoxO signaling pathway</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05167</td><td align="left" rowspan="1" colspan="1">Kaposi sarcoma-associated herpesvirus infection</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05224</td><td align="left" rowspan="1" colspan="1">Breast cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05226</td><td align="left" rowspan="1" colspan="1">Gastric cancer</td></tr><tr><td align="left" rowspan="1" colspan="1">KEGG</td><td align="left" rowspan="1" colspan="1">hsa05205</td><td align="left" rowspan="1" colspan="1">Proteoglycans in cancer</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>GO, gene ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, kyoto encyclopedia of genes and genomes.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="pone.0328881.g001" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g001</object-id><label>Fig 1</label><caption><title>Analysis of cellular senescence-related genes in THCA.</title><p><bold>(A)</bold> Volcano plot illustrating the distribution of DEGs in the TCGA-THCA dataset. Upregulated genes are indicated in orange and downregulated genes in blue. <bold>(B)</bold> Venn diagram showing the intersection of DEGs with genes associated with cellular senescence, highlighting overlapping genes. <bold>(C)</bold> GO enrichment analysis of DEGs associated with cellular senescence in THCA. The outer ring represents individual GO terms and their associated DEGs, color-coded by log fold change (Log FC), with upregulated genes in pink and downregulated genes in green. The inner heatmap ring visualizes the Z-score corresponding to each GO term, indicating the overall enrichment trend from downregulated (blue) to upregulated (red) terms. <bold>(D)</bold> KEGG pathway analysis of the 61 overlapping genes, depicting the major pathways they are involved in. The connections between pathways (hsa codes) and genes are color-coded based on LogFC, and the intensity represents the magnitude of differential expression. <bold>(E)</bold> Forest plot from univariate Cox regression analysis showing hazard ratios (HR) and 95% confidence intervals (CI) for nine key genes related to prognosis. <bold>(F)</bold> Protein-protein interaction (PPI) network of nine prognostic genes, with nodes representing genes and edges representing interactions. DEGs: Differentially Expressed Genes; TCGA: The Cancer Genome Atlas; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g001.jpg"/></fig></sec><sec id="sec027"><title>Identification of prognostic genes for THCA using LASSO regression and risk model evaluation</title><p>LASSO proportional hazards regression, combined with 10-fold cross-validation, was employed to detect potential prognostic genes. The optimal gene features were selected at lambda. min&#8201;=&#8201;0.0048, resulting in the identification of eight candidate genes (<xref rid="pone.0328881.g002" ref-type="fig">Figs 2A</xref>, <xref rid="pone.0328881.g002" ref-type="fig">2B</xref>). Risk scores were then determined for every patient, and based on the median cutoff point, patients were stratified into high-risk and low-risk groups. As shown in <xref rid="pone.0328881.g002" ref-type="fig">Fig 2C</xref>, a heatmap displays the survival outcomes of all patients and the expression patterns of the five characteristic genes (<italic toggle="yes">ETS2</italic>, <italic toggle="yes">CBX7</italic>, <italic toggle="yes">FASTK</italic>, <italic toggle="yes">SRSF1</italic>, <italic toggle="yes">MMP9</italic>). The Kaplan-Meier survival analysis demonstrates a significant difference in DFS between the high-risk and low-risk groups (<italic toggle="yes"><italic toggle="yes">P</italic>&#8201;</italic>=&#8201;0.000818). Patients in the high-risk group have a markedly worse DFS, with a hazard ratio (HR) of 7.764 (95% CI: 2.338&#8211;25.785), indicating they are approximately 7.8 times more likely to experience disease recurrence or progression compared to the low-risk group. The high-risk group shows a sharp decline in DFS probability within the first 5 years, while the low-risk group maintains a high DFS probability over time, highlighting the prognostic value of risk stratification (<xref rid="pone.0328881.g002" ref-type="fig">Fig 2D</xref>). The ROC curves that are time-dependent proved the prognostic accuracy of the risk model, with the highest AUC observed at one year (AUC&#8201;=&#8201;0.768), reflecting strong predictive performance (<xref rid="pone.0328881.g002" ref-type="fig">Fig 2E</xref>).</p><fig position="float" id="pone.0328881.g002" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g002</object-id><label>Fig 2</label><caption><title>LASSO Regression and Risk Model Evaluation for Prognostic Gene Identification in THCA.</title><p><bold>(A)</bold> LASSO regression plot depicting gene selection across different lambda values, with optimal lambda highlighted. <bold>(B)</bold> The coefficient plot from LASSO regression indicates the eight prognostic genes selected based on their coefficients. <bold>(C)</bold> Risk score distribution of TCGA-THCA patients (Top). Blue represents the low risk, and pink represents the high risk. Scatter plot of patient survival status (Middle). Blue represents the dead, and orange represents the alive. Heatmap of 5 prognostic signature gene expression profiles from low-risk to high-risk patients (Bottom). <bold>(D)</bold> Kaplan-Meier survival curves comparing overall survival between high-risk and low-risk groups based on the risk model. <bold>(E)</bold> ROC curves and AUC values for the risk model at 1-year, 3-year, and 5-year intervals, with the highest AUC at one year. LASSO: Least Absolute Shrinkage and Selection Operator; AUC: Area Under the Curve; ROC: Receiver Operating Characteristic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g002.jpg"/></fig></sec><sec id="sec028"><title>Prognostic value of ETS2 and clinical variables in THCA</title><p>Investigations of the five distinctive genes and clinical factors by univariate and multivariate Cox regression revealed that <italic toggle="yes">ETS2</italic> and pM stage are key prognostic factors (<xref rid="pone.0328881.g003" ref-type="fig">Figs 3A</xref>, <xref rid="pone.0328881.g003" ref-type="fig">3B</xref>). Consequently, <italic toggle="yes">ETS2</italic> was found to be a critical gene in this study. The nomogram analysis and calibration curves for key prognostic variables further demonstrated that <italic toggle="yes">ETS2</italic> possesses excellent predictive capability for the survival of patients at 1, 3, and 5 years (<xref rid="pone.0328881.g003" ref-type="fig">Figs 3C</xref>, <xref rid="pone.0328881.g003" ref-type="fig">3D</xref>). These results imply that <italic toggle="yes">ETS2</italic> could represent a valuable target for therapy and prognostic biomarkers in THCA.</p><fig position="float" id="pone.0328881.g003" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g003</object-id><label>Fig 3</label><caption><title>Cox regression analysis and nomogram for prognostic evaluation of THCA.</title><p><bold>(A)</bold> Univariate Cox regression analysis of prognostic signature genes and clinical variables, displaying hazard ratios (HR) and 95% confidence intervals (CI). <bold>(B)</bold> Multivariate Cox regression analysis assessing the prognostic value of prognostic signature genes along with clinical variables. <bold>(C)</bold> Nomogram for predicting 1-year, 3-year, and 5-year survival probabilities based on key prognostic factors, including <italic toggle="yes">ETS2</italic>. <bold>(D)</bold> Calibration plots comparing observed versus predicted survival probabilities for 1-year, 3-year, and 5-year survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g003.jpg"/></fig></sec><sec id="sec029"><title>Differential expression and prognostic significance of ETS2 in THCA</title><p>Pan-cancer analysis utilizing the GEPIA2 database revealed significant variation in <italic toggle="yes">ETS2</italic> expression across multiple cancer types. Notably, <italic toggle="yes">ETS2</italic> was discovered to be downregulated in various cancers, such as THCA, bladder cancer (BLCA), diffuse large B-cell lymphoma (DLBC), glioblastoma multiforme (GBM), and breast cancer (BRCA), with the most pronounced downregulation observed in THCA (<xref rid="pone.0328881.g004" ref-type="fig">Figs 4A</xref>, <xref rid="pone.0328881.g004" ref-type="fig">4B</xref>). revealed a substantial correlation between lower PFS and DFS and low <italic toggle="yes">ETS2</italic> expression (<xref rid="pone.0328881.g004" ref-type="fig">Figs 4C</xref>, <xref rid="pone.0328881.g004" ref-type="fig">4D</xref>). Additionally, IHC analysis demonstrated that <italic toggle="yes">ETS2</italic> expression was markedly higher in normal tissue relative to THCA tumor tissue (<xref rid="pone.0328881.g004" ref-type="fig">Fig 4E</xref>). These outcomes suggest that <italic toggle="yes">ETS2</italic> expression level perhaps connected to a poor prognosis and that it may be important in the initiation and development of THCA.</p><fig position="float" id="pone.0328881.g004" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g004</object-id><label>Fig 4</label><caption><title>Expression and prognostic relevance of <italic toggle="yes">ETS2</italic> in THCA.</title><p><bold>(A)</bold> Pan-cancer analysis showing the expression levels of <italic toggle="yes">ETS2</italic> across various cancer types, including THCA, with data represented as transcripts per million (TPM). <bold>(B)</bold> Box plot of <italic toggle="yes">ETS2</italic> expression between THCA tumor tissue (T) and adjacent normal tissue <bold>(N)</bold>. <bold>(C)</bold> Kaplan-Meier survival curves for progression-free survival (PFS) stratified by <italic toggle="yes">ETS2</italic> expression levels. <bold>(D)</bold> Kaplan-Meier survival curves for disease-free survival (DFS) associated with <italic toggle="yes">ETS2</italic> expression levels. <bold>(E)</bold> Immunohistochemical analysis of <italic toggle="yes">ETS2</italic> expression in normal thyroid tissue compared to THCA tumor tissue. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g004.jpg"/></fig></sec><sec id="sec030"><title>ETS2 overexpression inhibits THCA cell behavior</title><p>The expression of <italic toggle="yes">ETS2</italic> in several THCA cell lines (TPC-1, Cal-62, BC-PAP) was analyzed and compared with normal thyroid cells (Nthy-ori 3&#8211;1). qRT-PCR outcomes demonstrated that the mRNA expression of <italic toggle="yes">ETS2</italic> in both THCA cell lines (TPC-1, Cal-62) was significantly downregulated compared with normal thyroid cells (<xref rid="pone.0328881.g005" ref-type="fig">Fig 5A</xref>). WB analysis further verified the decreased protein level of ETS2 in these cancer cell lines (<xref rid="pone.0328881.g005" ref-type="fig">Fig 5B</xref>, <xref rid="pone.0328881.g005" ref-type="fig">5C</xref>). qRT-PCR and WB verified the transfection efficiency of <italic toggle="yes">ETS2</italic> overexpression plasmid in TPC-1 and Cal-62cells and confirmed the high expression of <italic toggle="yes">ETS2</italic> (<xref rid="pone.0328881.g005" ref-type="fig">Figs 5D</xref>&#8211;<xref rid="pone.0328881.g005" ref-type="fig">5G</xref>). CCK-8 assay showed a significant decrease in cell proliferation after <italic toggle="yes">ETS2</italic> overexpression, suggesting that it has a suppressive impact on the proliferation of THCA cells (<xref rid="pone.0328881.g005" ref-type="fig">Fig 5H</xref>, <xref rid="pone.0328881.g005" ref-type="fig">5I</xref>). In addition, Transwell experiments also found that after <italic toggle="yes">ETS2</italic> overexpression, the quantity of invasive and migrating cells was considerably decreased, suggesting that <italic toggle="yes">ETS2</italic> markedly reduced the migration and invasion ability of THCA cells (<xref rid="pone.0328881.g005" ref-type="fig">Figs 5J</xref>, <xref rid="pone.0328881.g005" ref-type="fig">5K</xref>), further supporting the function of <italic toggle="yes">ETS2</italic> overexpression in inhibiting the proliferation, invasion, and migration of THCA cells.</p><fig position="float" id="pone.0328881.g005" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g005</object-id><label>Fig 5</label><caption><title>Effects of <italic toggle="yes">ETS2</italic> overexpression on THCA cell behavior.</title><p><bold>(A)</bold> qRT-PCR analysis of <italic toggle="yes">ETS2</italic> mRNA expression in normal thyroid epithelial cells (Nthy-ori 3-1) and THCA cell lines (Cal-62, TPC-1, BC-PAP). <bold>(B-C)</bold> WB analysis showing ETS2 protein expression in normal thyroid epithelial cells versus thyroid cancer cell lines. <bold>(D-G)</bold> Verification of <italic toggle="yes">ETS2</italic> overexpression in Cal-62 and TPC-1 cells through qRT-PCR and WB assays. (H and <bold>I)</bold> CCK-8 assay illustrating the proliferation rates of Cal-62 and TPC-1 cells post-<italic toggle="yes">ETS2</italic> overexpression. <bold>(J and K)</bold> Transwell assay quantifying invasion and migration capabilities of Cal-62 and TPC-1 cells following <italic toggle="yes">ETS2</italic> overexpression. Scale bar: 50 &#956;m. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting; CCK-8: Cell Counting Kit-8. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g005.jpg"/></fig></sec><sec id="sec031"><title>ETS2 overexpression promotes apoptosis in THCA cells</title><p>Flow cytometry was utilized to evaluate the impact of <italic toggle="yes">ETS2</italic> overexpression on apoptosis in Cal-62 and TPC-1 cells. The outcomes revealed a notable rise in the quantity of Cal-62 and TPC-1 apoptotic cells following <italic toggle="yes">ETS2</italic> overexpression, indicating that <italic toggle="yes">ETS2</italic> enhances apoptosis in thyroid cancer cells (<xref rid="pone.0328881.g006" ref-type="fig">Figs 6A</xref>, <xref rid="pone.0328881.g006" ref-type="fig">6B</xref>). WB analysis was conducted to assess the results of <italic toggle="yes">ETS2</italic> overexpression on apoptosis-related proteins, including Bax, Bcl-2, Caspase-9, and Caspase-3. The outcomes revealed that <italic toggle="yes">ETS2</italic> overexpression led to increased expression of Caspase-9, Bax, and Caspase-3, while Bcl-2 expression was decreased in Cal-62 and TPC-1 cells (<xref rid="pone.0328881.g006" ref-type="fig">Figs 6C</xref>&#8211;<xref rid="pone.0328881.g006" ref-type="fig">6E</xref>). These findings suggest that <italic toggle="yes">ETS2</italic> overexpression promotes apoptosis in THCA cells by modulating the expression of key apoptotic regulators.</p><fig position="float" id="pone.0328881.g006" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g006</object-id><label>Fig 6</label><caption><title>Apoptotic effects of <italic toggle="yes">ETS2</italic> overexpression in THCA cells.</title><p><bold>(A and B)</bold> Flow cytometry analysis showing apoptosis rates in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression. <bold>(C)</bold> WB analysis of apoptosis-related proteins (Bax, Bcl-2, Caspase-3, Caspase-9) in THCA cells with <italic toggle="yes">ETS2</italic> overexpression. <bold>(D-E)</bold> Bar graph quantifying levels of pro-apoptotic (Bax, Caspase-3, Caspase-9) and anti-apoptotic (Bcl-2) proteins with <italic toggle="yes">ETS2</italic> overexpression. WB: Western Blotting. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g006.jpg"/></fig></sec><sec id="sec032"><title>ETS2 overexpression regulates EMT marker expression in THCA cells</title><p>The EMT process enables cancer cells to acquire enhanced migratory and invasive capabilities. This study investigated the impact of <italic toggle="yes">ETS2</italic> overexpression on the levels of proteins linked to EMT in THCA cells. qRT-PCR findings showed that <italic toggle="yes">ETS2</italic> overexpression suppressed the mRNA expression of <italic toggle="yes">N-cadherin</italic>, <italic toggle="yes">Vimentin</italic>, <italic toggle="yes">ZEB1</italic>, <italic toggle="yes">ZEB2</italic>, <italic toggle="yes">Slug</italic>, and <italic toggle="yes">Snail</italic> and enhanced the mRNA expression of <italic toggle="yes">E-cadherin</italic> in comparison to the control group (<xref rid="pone.0328881.g007" ref-type="fig">Figs 7A</xref>, <xref rid="pone.0328881.g007" ref-type="fig">7B</xref>). WB analysis corroborated these findings at the protein level (<xref rid="pone.0328881.g007" ref-type="fig">Figs 7C</xref>&#8211;<xref rid="pone.0328881.g007" ref-type="fig">7E</xref>). These results demonstrate that <italic toggle="yes">ETS2</italic> overexpression can reverse the EMT process in THCA cells, suggesting a possible involvement in preventing progression and metastasis.</p><fig position="float" id="pone.0328881.g007" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g007</object-id><label>Fig 7</label><caption><title>Effect of <italic toggle="yes">ETS2</italic> overexpression on the expression of EMT markers in THCA cells.</title><p><bold>(A-B)</bold> qRT-PCR analysis of EMT-related gene mRNA levels (<italic toggle="yes">E-cadherin</italic>, <italic toggle="yes">N-cadherin</italic>, <italic toggle="yes">Vimentin</italic>, <italic toggle="yes">ZEB1</italic>, <italic toggle="yes">ZEB2</italic>, <italic toggle="yes">Snail</italic>, <italic toggle="yes">Slug</italic>) in THCA cells with <italic toggle="yes">ETS2</italic> overexpression. <bold>(C)</bold> WB analysis confirms the effects of <italic toggle="yes">ETS2</italic> overexpression at the protein level. <bold>(D-E)</bold> Quantification of EMT protein expression levels with <italic toggle="yes">ETS2</italic> overexpression. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting; EMT: Epithelial-Mesenchymal Transition. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g007.jpg"/></fig></sec><sec id="sec033"><title>Validation of the interaction between ETS2 and ZMYND11 in THCA cells</title><p>To learn more about the connection between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic>, Co-IP and expression analysis were performed. Co-IP results demonstrated that ZMYND11 interacts with ETS2 in the THCA cell lines (<xref rid="pone.0328881.g008" ref-type="fig">Fig 8A</xref>). Subsequent qRT-PCR analysis revealed that <italic toggle="yes">ETS2</italic> overexpression significantly increased <italic toggle="yes">ZMYND11</italic> mRNA levels in both cell lines, with a more pronounced effect observed in TPC-1 cells (<xref rid="pone.0328881.g008" ref-type="fig">Fig 8B</xref>). In line with the mRNA results, WB analysis verified a noteworthy rise in ZMYND11 protein levels following ETS2 overexpression in THCA cell lines (<xref rid="pone.0328881.g008" ref-type="fig">Figs 8C</xref>, <xref rid="pone.0328881.g008" ref-type="fig">8D</xref>). These findings suggest that <italic toggle="yes">ETS2</italic> positively regulates <italic toggle="yes">ZMYND11</italic> expression in THCA cells.</p><fig position="float" id="pone.0328881.g008" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g008</object-id><label>Fig 8</label><caption><title>Interaction between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in THCA cells.</title><p><bold>(A)</bold> Co-immunoprecipitation results confirm the interaction between ETS2 and ZMYND11 in Cal-62 and TPC-1 cells. IP: Immunoprecipitation, IN: input. <bold>(B)</bold> qRT-PCR analysis showing the impact of <italic toggle="yes">ETS2</italic> overexpression on <italic toggle="yes">ZMYND11</italic> expression in Cal-62 and TPC-1 cells. <bold>(C)</bold> WB analysis of ZMYND11 expression levels in cells with ETS2 overexpression. <bold>(D)</bold> Bar graph illustrating changes in ZMYND11 expression due to ETS2 overexpression. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g008.jpg"/></fig></sec><sec id="sec034"><title>ZMYND11 knockdown attenuates the inhibitory effect of ETS2 overexpression on THCA cell behavior</title><p>To investigate the functional relationship between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in THCA cells, <italic toggle="yes">ZMYND11</italic> knockdown was performed using siRNA in Cal-62 and TPC-1 cells. qRT-PCR and WB analysis confirmed that <italic toggle="yes">ZMYND11</italic> mRNA and protein levels were greatly decreased after siRNA transfection in comparison to the control (<xref rid="pone.0328881.g009" ref-type="fig">Fig 9A</xref>&#8211;<xref rid="pone.0328881.g009" ref-type="fig">9C</xref>). Subsequent knockdown of <italic toggle="yes">ZMYND11</italic> in <italic toggle="yes">ETS2</italic>-overexpressing cells caused <italic toggle="yes">ZMYND11</italic> expression to significantly decline at the levels of proteins and Mrna (<xref rid="pone.0328881.g009" ref-type="fig">Fig 9D</xref>&#8211;<xref rid="pone.0328881.g009" ref-type="fig">9F</xref>). Functionally, the knockdown of <italic toggle="yes">ZMYND11</italic> partially reversed the restraint of <italic toggle="yes">ETS2</italic> overexpression on cell growth, as confirmed by the CCK-8 assay in both TPC-1 and Cal-62 cells (<xref rid="pone.0328881.g009" ref-type="fig">Fig 9J</xref>, <xref rid="pone.0328881.g009" ref-type="fig">9K</xref>). Furthermore, Transwell assays indicated that the enhanced invasion and migration abilities observed in <italic toggle="yes">ETS2</italic>-overexpressing cells were significantly attenuated after <italic toggle="yes">ZMYND11</italic> knockdown (<xref rid="pone.0328881.g009" ref-type="fig">Figs 9L</xref>, <xref rid="pone.0328881.g009" ref-type="fig">9M</xref>). These results suggest that <italic toggle="yes">ZMYND11</italic> mediates the way that <italic toggle="yes">ETS2</italic> affects THCA cell invasion, migration, and proliferation, highlighting the functional interaction between these two genes.</p><fig position="float" id="pone.0328881.g009" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g009</object-id><label>Fig 9</label><caption><title><italic toggle="yes">ZMYND11</italic> knockdown reverses the effects of <italic toggle="yes">ETS2</italic> overexpression on cell proliferation, migration, and invasion in THCA cells.</title><p><bold>(A)</bold> qRT-PCR analysis of <italic toggle="yes">ZMYND11</italic> knockdown efficiency in Cal-62 and TPC-1 cells. <bold>(B)</bold> WB analysis showing ZMYND11 protein expression levels post-knockdown. <bold>(C)</bold> Bar graph illustrating a reduction in ZMYND11 expression following knockdown. <bold>(D)</bold> qRT-PCR results assessing <italic toggle="yes">ZMYND11</italic> levels in Cal-62 cell with <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(E-F)</bold> WB analysis of ZMYND11 expression in Cal-62 cell with combined ETS2 overexpression and ZMYND11 knockdown. <bold>(G)</bold> qRT-PCR results assessing <italic toggle="yes">ZMYND11</italic> levels in TPC-1 cell with <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(H-I)</bold> WB analysis of ZMYND11 expression in TPC-1 cell with combined ETS2 overexpression and ZMYND11 knockdown. <bold>(J-K)</bold> CCK-8 assay depicting cell proliferation in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(L-M)</bold> Transwell assay results for cell invasion and migration in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown. Scale bar: 50 &#956;m. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting; CCK-8: Cell Counting Kit-8. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g009.jpg"/></fig></sec><sec id="sec035"><title>ZMYND11 knockdown reverses ETS2-mediated apoptosis in THCA cells</title><p>To discover the role of <italic toggle="yes">ZMYND11</italic> in <italic toggle="yes">ETS2</italic>-induced apoptosis in THCA cells, flow cytometry and expression analysis of apoptosis-related genes were performed. Flow cytometry with Annexin V/PI staining demonstrated that <italic toggle="yes">ETS2</italic> overexpression notably elevated apoptosis in TPC-1 and Cal-62 cells relative to the control group. However, <italic toggle="yes">ZMYND11</italic> knockdown in <italic toggle="yes">ETS2</italic>-overexpressing cells markedly reduced the percentage of apoptotic cells (<xref rid="pone.0328881.g010" ref-type="fig">Figs 10A</xref>, <xref rid="pone.0328881.g010" ref-type="fig">10B</xref>). Gene expression analysis by qRT-PCR showed that <italic toggle="yes">ETS2</italic> overexpression led to a significant rise in pro-apoptotic genes and a decrease in the anti-apoptotic gene in Cal-62 and TPC-1 cells. Knockdown of <italic toggle="yes">ZMYND11</italic> reversed these changes, restored <italic toggle="yes">Bcl-2</italic> levels, and reduced the levels of pro-apoptotic genes (<xref rid="pone.0328881.g010" ref-type="fig">Figs 10C</xref>, <xref rid="pone.0328881.g010" ref-type="fig">10D</xref>). WB analysis further confirmed these findings at the protein level, indicating that in <italic toggle="yes">ETS2</italic>-overexpressing cells, <italic toggle="yes">ZMYND11</italic> knockdown decreased Caspase-9, Caspase-3, and Bax levels while raising Bcl-2 protein expression (<xref rid="pone.0328881.g010" ref-type="fig">Figs 10E</xref>, <xref rid="pone.0328881.g010" ref-type="fig">10F</xref>, <xref rid="pone.0328881.g010" ref-type="fig">10G</xref>). These findings imply that ZMYND11 is crucial for mediating the ETS2-induced apoptosis that occurs in THCA cells.</p><fig position="float" id="pone.0328881.g010" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g010</object-id><label>Fig 10</label><caption><title><italic toggle="yes">ZMYND11</italic> knockdown reverses <italic toggle="yes">ETS2</italic>-induced apoptosis in THCA cells.</title><p><bold>(A and B)</bold> Flow cytometry analysis showing apoptotic rates in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(C</bold> and <bold>D)</bold> qRT-PCR analysis of apoptosis-related genes (<italic toggle="yes">Bax</italic>, <italic toggle="yes">Bcl-2</italic>, <italic toggle="yes">Caspase-3</italic>, <italic toggle="yes">Caspase-9</italic>) under <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown conditions. <bold>(E)</bold> WB analysis of apoptosis-related proteins (Bax, Bcl-2, Caspase-3, Caspase-9) under <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown conditions. <bold>(F and G)</bold> Bar graph quantifying changes in apoptosis-related protein levels. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g010.jpg"/></fig></sec><sec id="sec036"><title>ZMYND11 knockdown reverses ETS2-induced EMT marker expression in THCA cells</title><p>We investigated the impacts of <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown on the expression levels of EMT-related proteins to learn more about whether <italic toggle="yes">ZMYND11</italic> and <italic toggle="yes">ETS2</italic> affect the EMT process in THCA cells. qRT-PCR results demonstrated that <italic toggle="yes">ETS2</italic> overexpression markedly elevated the levels of <italic toggle="yes">E-cadherin</italic> while suppressing the levels of <italic toggle="yes">Vimentin</italic>, <italic toggle="yes">N-cadherin</italic>, <italic toggle="yes">ZEB1</italic>, <italic toggle="yes">ZEB2</italic>, <italic toggle="yes">Snail</italic>, and <italic toggle="yes">Slug</italic> in contrast to the group under control. On the other hand, <italic toggle="yes">ETS2</italic> overexpression and <italic toggle="yes">ZMYND11</italic> knockdown caused a decline in <italic toggle="yes">E-cadherin</italic> expression and a significant increase in <italic toggle="yes">Vimentin</italic>, <italic toggle="yes">N-cadherin</italic>, <italic toggle="yes">ZEB1</italic>, <italic toggle="yes">ZEB2</italic>, <italic toggle="yes">Snail</italic>, and <italic toggle="yes">Slug</italic> expression (<xref rid="pone.0328881.g011" ref-type="fig">Figs 11A</xref>, <xref rid="pone.0328881.g011" ref-type="fig">11B</xref>). These results were further supported by WB analysis, which validated the observed changes at the protein level (<xref rid="pone.0328881.g011" ref-type="fig">Figs 11C</xref>&#8211;<xref rid="pone.0328881.g011" ref-type="fig">11E</xref>). Overall, these findings suggest that <italic toggle="yes">ETS2</italic> is essential for controlling the EMT process, and its effects may be mediated through modulation of <italic toggle="yes">ZMYND11</italic> expression.</p><fig position="float" id="pone.0328881.g011" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g011</object-id><label>Fig 11</label><caption><title><italic toggle="yes">ZMYND11</italic> knockdown reverses <italic toggle="yes">ETS2</italic>-induced changes in EMT marker expression in THCA cells.</title><p><bold>(A)</bold> qRT-PCR analysis of EMT marker (<italic toggle="yes">E-cadherin</italic>, <italic toggle="yes">N-cadherin</italic>, <italic toggle="yes">Vimentin</italic>, <italic toggle="yes">ZEB1</italic>, <italic toggle="yes">ZEB2</italic>, <italic toggle="yes">Snail</italic>, <italic toggle="yes">Slug</italic>) in Cal-62 cells after <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(B)</bold> Bar graph showing the changes in the mRNA levels of EMT markers in TPC-1 cells after <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(C)</bold> WB analysis of EMT proteins (E-cadherin, N-cadherin, Vimentin, ZEB1, ZEB2, Snail, Slug) following <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(D and E)</bold> Quantification of EMT protein expression levels with <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. EMT: Epithelial-Mesenchymal Transition; qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g011.jpg"/></fig></sec><sec id="sec037"><title>ZMYND11 knockdown regulates ETS2-mediated regulation of mTOR pathway-related genes</title><p>Finally, to explore the effect of <italic toggle="yes">ZMYND11</italic> on <italic toggle="yes">ETS2</italic>-mediated regulation of genes linked to the mTOR pathway, we analyzed the expression levels of key signaling molecules in THCA cells. qRT-PCR analysis revealed that <italic toggle="yes">ETS2</italic> overexpression significantly decreased the mRNA expression in both cell lines. However, the knockdown of <italic toggle="yes">ZMYND11</italic> in <italic toggle="yes">ETS2</italic>-overexpressing cells reversed this effect, resulting in a notable rise in the levels of <italic toggle="yes">S6K1</italic>, <italic toggle="yes">NF-&#954;B1</italic>, <italic toggle="yes">COX2</italic>, and <italic toggle="yes">4EBP1</italic> (<xref rid="pone.0328881.g012" ref-type="fig">Figs 12A</xref>, <xref rid="pone.0328881.g012" ref-type="fig">12B</xref>). Similar to the mRNA results, this result was also confirmed at the protein level (<xref rid="pone.0328881.g012" ref-type="fig">Figs 12C</xref>&#8211;<xref rid="pone.0328881.g012" ref-type="fig">12E</xref>). These findings suggest that <italic toggle="yes">ZMYND11</italic> is essential for controlling <italic toggle="yes">ETS2</italic>-mediated regulation of the mTOR signaling cascade in THCA cells.</p><fig position="float" id="pone.0328881.g012" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g012</object-id><label>Fig 12</label><caption><title><italic toggle="yes">ZMYND11</italic> knockdown reverses <italic toggle="yes">ETS2</italic>-mediated downregulation of mTOR signaling pathway-related genes in THCA cells.</title><p><bold>(A</bold> and <bold>B)</bold> qRT-PCR analysis of mTOR pathway-related genes (<italic toggle="yes">S6K1</italic>, <italic toggle="yes">NF-&#954;B1</italic>, <italic toggle="yes">COX2</italic>, <italic toggle="yes">4EBP1</italic>) in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(C)</bold> WB analysis of mTOR signaling pathway proteins (S6K1, NF-&#954;B1, COX2, 4EBP1) in Cal-62 and TPC-1 cells with <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. <bold>(D-E)</bold> Bar graph quantifying mTOR pathway protein levels with <italic toggle="yes">ETS2</italic> overexpression and/or <italic toggle="yes">ZMYND11</italic> knockdown. qRT-PCR: Quantitative Reverse Transcription Polymerase Chain Reaction; WB: Western Blotting. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05, <sup>#</sup><italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g012.jpg"/></fig></sec><sec id="sec038"><title><italic toggle="yes">ETS2</italic> overexpression suppresses tumor growth <italic toggle="yes">in vivo</italic></title><p>To further validate the tumor-suppressive role of <italic toggle="yes">ETS2</italic> in thyroid cancer, we established a mouse xenograft model using Cal-62 cells overexpressing <italic toggle="yes">ETS2</italic> or a control vector. The results showed that, compared with the control group, tumors derived from the <italic toggle="yes">ETS2</italic> overexpression group exhibited a significantly reduced weight, indicating that <italic toggle="yes">ETS2</italic> inhibits tumor growth in vivo (<xref rid="pone.0328881.g013" ref-type="fig">Fig 13A</xref>, <xref rid="pone.0328881.g013" ref-type="fig">13B</xref>). In addition, IHC staining was performed on xenograft tumor tissues to assess the expression of ETS2 and ZMYND11 (<xref rid="pone.0328881.g013" ref-type="fig">Fig 13C</xref>). The results revealed a marked increase in both ETS2 and ZMYND11 expression in the <italic toggle="yes">ETS2</italic> overexpression group compared to the vector group. These findings are consistent with our <italic toggle="yes">in vitro</italic> data and suggest that <italic toggle="yes">ETS2</italic> not only inhibits tumor growth but may also positively regulate <italic toggle="yes">ZMYND11</italic> expression in thyroid cancer tissues.</p><fig position="float" id="pone.0328881.g013" orientation="portrait"><object-id pub-id-type="doi">10.1371/journal.pone.0328881.g013</object-id><label>Fig 13</label><caption><title>Overexpression of <italic toggle="yes">ETS2</italic> inhibits tumor growth <italic toggle="yes">in vivo.</italic></title><p><bold>(A)</bold> Representative images of xenograft tumors formed by Cal-62 cells transfected with empty vector or <italic toggle="yes">ETS2</italic>-overexpressing plasmid (over-<italic toggle="yes">ETS2</italic>) in nude mice. <bold>(B)</bold> Quantification of tumor weight in the vector and over-<italic toggle="yes">ETS2</italic> groups. *<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05. <bold>(C)</bold> IHC staining of ETS2 and ZMYND11 in xenograft tumor tissues. Magnification: 20x. IHC: Immunohistochemical.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pone.0328881.g013.jpg"/></fig></sec></sec><sec sec-type="conclusions" id="sec039"><title>Discussion</title><p>Previous investigations have identified the presence of senescent cells and cancer-associated fibroblasts (CAFs) in various thyroid cancer subtypes, including papillary, poorly differentiated, and anaplastic thyroid cancers [<xref rid="pone.0328881.ref016" ref-type="bibr">16</xref>]. These cells were found to coexist at the invasive edges of tumors, particularly in cases with BRAF mutations or BRAF-like molecular subtypes, correlating with local invasion [<xref rid="pone.0328881.ref017" ref-type="bibr">17</xref>]. In the present study, analysis of the TCGA-THCA dataset identified 61 DEGs associated with cellular senescence pathways, with <italic toggle="yes">ETS2</italic> emerging as a key prognostic gene. ETS2, known for its dual role in regulating cell proliferation and apoptosis, was markedly downregulated in THCA, and lower expression of <italic toggle="yes">ETS2</italic> was connected to poorer PFS and DFS. IHC analysis confirmed reduced ETS2 protein levels in THCA tissues in contrast to typical tissues, underscoring its capability to serve as a therapeutic target and biomarker. Additionally, previous research by Ren Y et al. highlighted distinct roles of <italic toggle="yes">ETS1</italic> and <italic toggle="yes">ETS2</italic> across cancers, with <italic toggle="yes">ETS1</italic> involved in oxidative stress regulation and ETS2 in transcriptional control [<xref rid="pone.0328881.ref018" ref-type="bibr">18</xref>]. Thus, further investigation into the function of <italic toggle="yes">ETS2</italic> in THCA could offer insightful information about therapy.</p><p><italic toggle="yes">ETS2</italic>, a gene involved in cellular response and senescence, is a key factor in thyroid cancer progression [<xref rid="pone.0328881.ref019" ref-type="bibr">19</xref>]. A complicated relationship between <italic toggle="yes">ETS2</italic> and several signaling pathways has been identified by recent investigations. For instance, Yin X. et al. demonstrated that elevated exosomal miR-663b in bladder cancer targets <italic toggle="yes">ETS2</italic> inhibitors and promotes proliferation and EMT [<xref rid="pone.0328881.ref020" ref-type="bibr">20</xref>]. Similarly, Ichikawa MK. et al. highlighted the function of <italic toggle="yes">ETS2</italic> in senescence, enhancing the levels of <italic toggle="yes">Snail</italic> and <italic toggle="yes">ZEB1/2</italic> under TGF-&#946; and Ras signaling [<xref rid="pone.0328881.ref021" ref-type="bibr">21</xref>]. EMT plays a crucial part in embryonic development, tissue regeneration, and cancer metastasis [<xref rid="pone.0328881.ref022" ref-type="bibr">22</xref>]. It is defined by the upregulation of mesenchymal markers like <italic toggle="yes">Vimentin</italic> and <italic toggle="yes">N-cadherin</italic> and the reduction of epithelial markers like <italic toggle="yes">E-cadherin</italic>. This process is regulated by transcription-related factors including <italic toggle="yes">Slug</italic>, <italic toggle="yes">Snail</italic>, <italic toggle="yes">ZEB2</italic>, and <italic toggle="yes">ZEB1</italic>. In THCA, EMT enhances invasiveness and metastasis, leading to a poor prognosis. Genes and pathways associated with EMT, including PI3K/AKT and MAPK/EMT, have been implicated in THCA progression [<xref rid="pone.0328881.ref023" ref-type="bibr">23</xref>]. Inhibition or reversal of EMT, for example by targeting the interaction of <italic toggle="yes">HER2</italic> with the MAPK/EMT pathway, could provide a potential therapeutic strategy. EMT also supports the maintenance of stem cells for cancer, increasing tumor invasiveness and treatment refractoriness [<xref rid="pone.0328881.ref024" ref-type="bibr">24</xref>]. Our results demonstrate that <italic toggle="yes">ETS2</italic> overexpression in THCA cells inhibits migration, proliferation, and invasion while enhancing apoptosis and regulating the levels of EMT-related markers. This highlights <italic toggle="yes">ETS2</italic> as a possible therapeutic objective for THCA.</p><p>The results of this investigation underscore the significant regulatory roles of <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in THCA and their impact on tumor progression. <italic toggle="yes">ZMYND11</italic>, characterized by its MYND domain, is crucial in protein-protein interactions and transcriptional regulation. In cancer, <italic toggle="yes">ZMYND11</italic> modulates gene expression related to the cell cycle, differentiation, and apoptosis, influencing tumor growth [<xref rid="pone.0328881.ref025" ref-type="bibr">25</xref>]. For instance, Zhang Z. et al. identified that elevated microRNA-196b in ovarian cancer promotes cell proliferation, invasion, and migration by targeting <italic toggle="yes">ZMYND11</italic>, suggesting that its function can be modulated by specific microRNAs, with abnormal expression contributing to malignancy [<xref rid="pone.0328881.ref026" ref-type="bibr">26</xref>]. Additionally, Meng X. et al. demonstrated that USP53 interacts with <italic toggle="yes">ZMYND11</italic> to enhance its deubiquitination and stability, inhibiting breast cancer cell proliferation and inducing apoptosis [<xref rid="pone.0328881.ref027" ref-type="bibr">27</xref>]. Recent studies also suggest that ETS1, another member of the ETS transcription factor family, may crosstalk with ETS2 in regulating ZMYND11 expression and its downstream effects [<xref rid="pone.0328881.ref013" ref-type="bibr">13</xref>]. ETS1 has been implicated in various cancers, including lung and breast cancer, where it cooperates with other transcription factors like ETS2 to influence gene expression related to cell invasion and metastasis [<xref rid="pone.0328881.ref028" ref-type="bibr">28</xref>]. The potential interaction between ETS1 and ZMYND11 in the context of THCA could provide a more complex regulatory mechanism underlying tumor progression. Our study confirms the direct interaction between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in THCA cells through Co-IP assay, showing that <italic toggle="yes">ZMYND11</italic> knockdown can counteract the impacts of overexpressing <italic toggle="yes">ETS2</italic> on invasion, proliferation, migration, apoptosis, and EMT. These findings emphasize the vital function of <italic toggle="yes">ETS2</italic> in regulating these processes, mediated through its interaction with <italic toggle="yes">ZMYND11</italic>. Understanding the <italic toggle="yes">ETS2</italic>-<italic toggle="yes">ZMYND11</italic> axis offers deeper insights into their collaborative role in thyroid cancer and suggests potential therapeutic targets for THCA management.</p><p>The mTOR pathway regulates essential cellular functions including proliferation, growth, metabolism, and survival, a crucial signaling network [<xref rid="pone.0328881.ref029" ref-type="bibr">29</xref>]. mTOR, a serine/threonine kinase, integrates environmental signals, including nutrients, oxygen, and energy status, to regulate cell behavior [<xref rid="pone.0328881.ref030" ref-type="bibr">30</xref>]. Earlier investigations have highlighted the function of mTOR in THCA. For example, Derwich A. et al. reviewed the expression of proteins and genes linked to mTOR in papillary thyroid carcinoma (PTC) and their association with disease risk and clinical outcomes [<xref rid="pone.0328881.ref031" ref-type="bibr">31</xref>]. Similarly, Lv J. et al. demonstrated that M2 tumor-associated macrophages (TAMs) promote the invasiveness and stemness of anaplastic thyroid carcinoma (ATC) cells by secreting IGF-1 and IGF-2, thereby activating the IR-A/IGF1R-mediated PI3K/AKT/mTOR signaling pathway [<xref rid="pone.0328881.ref032" ref-type="bibr">32</xref>]. mTORC1, a key part of the mTOR pathway, promotes protein synthesis by activating S6K1 and inhibiting eukaryotic translation initiation factor 4E-BP1 [<xref rid="pone.0328881.ref033" ref-type="bibr">33</xref>]. Additionally, the mTOR pathway can modulate NF-&#954;B1 activity and influence COX2 expression, contributing to inflammation and cancer progression [<xref rid="pone.0328881.ref034" ref-type="bibr">34</xref>]. Our research examined the functions of <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in modulating the mTOR signaling pathway in THCA cells. Our findings indicate that <italic toggle="yes">ETS2</italic> overexpression significantly reduces the expression levels of S6K1, NF-&#954;B1, COX2, and 4E-BP1. However, when <italic toggle="yes">ETS2</italic> overexpression is combined with <italic toggle="yes">ZMYND11</italic> knockdown, the expression levels of these mTOR pathway components are restored. This suggests that the regulatory impact of <italic toggle="yes">ETS2</italic> on the mTOR pathway is mediated through its interaction with <italic toggle="yes">ZMYND11</italic>. These results highlight the complex interplay between <italic toggle="yes">ETS2</italic>, <italic toggle="yes">ZMYND11</italic>, and the mTOR signaling pathway in THCA cells, providing novel perspectives into potential pathways of THCA development and therapeutic targets.</p><p>In our study, while we have made significant progress in understanding the roles of <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic> in thyroid cancer, we must acknowledge that our research has certain limitations. Firstly, a notable limitation of our study is the absence of in vivo validation using thyroid cancer animal models. Secondly, our investigation into the specific mechanisms by which ETS2 and ZMYND11 regulate the mTOR signaling pathway, while suggestive, lacks depth. The precise molecular interactions and downstream effects require further elucidation. Thirdly, our analysis of the correlation between ETS2 and ZMYND11 expression and patient prognosis, although indicative, is limited by a relatively small sample size. This restricts the generalizability of our conclusions. Lastly, our study did not yield breakthrough findings in terms of novel mechanisms. The field is in need of innovative discoveries that can significantly advance our understanding of THCA pathogenesis. In summary, while our study provides a comprehensive analysis of ETS2 and ZMYND11 in THCA, it is essential to address these limitations through future research that incorporates in vivo models, advanced molecular techniques, larger sample sizes, and a focus on uncovering novel mechanisms. This will lead to a more profound understanding of THCA and potentially identify new therapeutic strategies.</p></sec><sec sec-type="conclusions" id="sec040"><title>Conclusion</title><p>This study shows that the cellular senescence-related gene <italic toggle="yes">ETS2</italic> has a major function in controlling cell proliferation, apoptosis, and EMT in THCA. Overexpression of <italic toggle="yes">ETS2</italic> inhibits the growth, invasion, and migration of THCA cells while promoting apoptosis. The interaction between <italic toggle="yes">ETS2</italic> and <italic toggle="yes">ZMYND11</italic>, and knockdown of <italic toggle="yes">ZMYND11</italic> reverses these effects, restoring key components of the mTOR pathway and EMT markers. These results emphasize the significance of the <italic toggle="yes">ETS2</italic>-<italic toggle="yes">ZMYND11</italic> axis in cellular senescence and thyroid cancer progression, underscoring its possible use as a THCA treatment target.</p></sec><sec id="sec041" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0328881.s001" position="float" content-type="local-data" orientation="portrait"><label>Supplementary File 1</label><caption><title>Unprocessed original Western blot images for Figures 5B&#8211;12C.</title><p>(PDF)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0328881.s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0328881.s002" position="float" content-type="local-data" orientation="portrait"><label>Supplementary File 2</label><caption><title>Unprocessed original Co-IP blots for Figure 8A.</title><p>(RAR)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0328881.s002.rar" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0328881.s003" position="float" content-type="local-data" orientation="portrait"><label>Supplementary File 3</label><caption><title>Unprocessed raw data of Transwell invasion and migration assays in Figures 9L and 9M.</title><p>(RAR)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0328881.s003.rar" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="pone.0328881.s004" position="float" content-type="local-data" orientation="portrait"><label>Supplementary File 4</label><caption><title>Raw data files for apoptosis analysis are presented in Figures 10A and 10B.</title><p>(RAR)</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pone.0328881.s004.rar" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><p>None.</p></ack><ref-list><title>References</title><ref id="pone.0328881.ref001"><label>1</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>L</given-names></name>. <article-title>Identification and Validation of a Prognostic Signature for Thyroid Cancer Based on Ferroptosis-Related Genes</article-title>. <source>Genes (Basel)</source>. <year>2022</year>;<volume>13</volume>(<issue>6</issue>):<fpage>997</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/genes13060997</pub-id><pub-id pub-id-type="pmid">35741758</pub-id><pub-id pub-id-type="pmcid">PMC9222385</pub-id></mixed-citation></ref><ref id="pone.0328881.ref002"><label>2</label><mixed-citation publication-type="book"><name name-style="western"><surname>Lam</surname><given-names>AK</given-names></name>. <article-title>Papillary thyroid carcinoma: current position in epidemiology, genomics, and classification</article-title>. <source>Papillary Thyroid Carcinoma: Methods and Protocols</source>. <publisher-name>Springer</publisher-name>; <year>2022</year>. p. <fpage>1</fpage>&#8211;<lpage>15</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-0716-2505-7_1</pub-id><pub-id pub-id-type="pmid">35670964</pub-id></mixed-citation></ref><ref id="pone.0328881.ref003"><label>3</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Han</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Cancer incidence and mortality in China, 2022</article-title>. <source>J Natl Cancer Cent</source>. <year>2024</year>;<volume>4</volume>(<issue>1</issue>):<fpage>47</fpage>&#8211;<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jncc.2024.01.006</pub-id><pub-id pub-id-type="pmid">39036382</pub-id><pub-id pub-id-type="pmcid">PMC11256708</pub-id></mixed-citation></ref><ref id="pone.0328881.ref004"><label>4</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ping</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>. <article-title>Thyroid cancer: incidence and mortality trends in China, 2005&#8211;2015</article-title>. <source>Endocrine</source>. <year>2020</year>;<volume>68</volume>:<fpage>163</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32002755</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12020-020-02207-6</pub-id></mixed-citation></ref><ref id="pone.0328881.ref005"><label>5</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nabhan</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dedhia</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Ringel</surname><given-names>MD</given-names></name>. <article-title>Thyroid cancer, recent advances in diagnosis and therapy</article-title>. <source>Int J Cancer</source>. <year>2021</year>;<volume>149</volume>(<issue>5</issue>):<fpage>984</fpage>&#8211;<lpage>92</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/ijc.33690</pub-id><pub-id pub-id-type="pmid">34013533</pub-id></mixed-citation></ref><ref id="pone.0328881.ref006"><label>6</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dong</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>F</given-names></name>. <article-title>Cellular senescence and SASP in tumor progression and therapeutic opportunities</article-title>. <source>Mol Cancer</source>. <year>2024</year>;<volume>23</volume>(<issue>1</issue>):<fpage>181</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12943-024-02096-7</pub-id><pub-id pub-id-type="pmid">39217404</pub-id><pub-id pub-id-type="pmcid">PMC11365203</pub-id></mixed-citation></ref><ref id="pone.0328881.ref007"><label>7</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hong</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Cen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Mai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name>. <article-title>Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<fpage>1128390</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fimmu.2023.1128390</pub-id><pub-id pub-id-type="pmid">36761753</pub-id><pub-id pub-id-type="pmcid">PMC9902917</pub-id></mixed-citation></ref><ref id="pone.0328881.ref008"><label>8</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>L-Y</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>X-J</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J-F</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>Y-R</given-names></name>. <article-title>The roles of ETS transcription factors in liver fibrosis</article-title>. <source>Hum Cell</source>. <year>2023</year>;<volume>36</volume>(<issue>2</issue>):<fpage>528</fpage>&#8211;<lpage>39</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13577-022-00848-5</pub-id><pub-id pub-id-type="pmid">36547849</pub-id></mixed-citation></ref><ref id="pone.0328881.ref009"><label>9</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>RNA-binding protein CELF1 enhances cell migration, invasion, and chemoresistance by targeting ETS2 in colorectal cancer</article-title>. <source>Clin Sci (Lond)</source>. <year>2020</year>;<volume>134</volume>(<issue>14</issue>):<fpage>1973</fpage>&#8211;<lpage>90</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1042/CS20191174</pub-id><pub-id pub-id-type="pmid">32677671</pub-id></mixed-citation></ref><ref id="pone.0328881.ref010"><label>10</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sang</surname><given-names>Y</given-names></name>. <article-title>The interaction between ETS transcription factor family members and microRNAs: A novel approach to cancer therapy</article-title>. <source>Biomed Pharmacother</source>. <year>2022</year>;<volume>150</volume>:<fpage>113069</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113069</pub-id><pub-id pub-id-type="pmid">35658214</pub-id></mixed-citation></ref><ref id="pone.0328881.ref011"><label>11</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xiang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>B</given-names></name>. <article-title>Identification and validation of senescence-related genes in circulating endothelial cells of patients with acute myocardial infarction</article-title>. <source>Front Cardiovasc Med</source>. <year>2022</year>;<volume>9</volume>:<fpage>1057985</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3389/fcvm.2022.1057985</pub-id><pub-id pub-id-type="pmid">36582740</pub-id><pub-id pub-id-type="pmcid">PMC9792765</pub-id></mixed-citation></ref><ref id="pone.0328881.ref012"><label>12</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Trivedi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Zinc finger myeloid Nervy DEAF-1 type (ZMYND) domain containing proteins exert molecular interactions to implicate in carcinogenesis</article-title>. <source>Discov Oncol</source>. <year>2022</year>;<volume>13</volume>(<issue>1</issue>):<fpage>139</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s12672-022-00597-9</pub-id><pub-id pub-id-type="pmid">36520265</pub-id><pub-id pub-id-type="pmcid">PMC9755447</pub-id></mixed-citation></ref><ref id="pone.0328881.ref013"><label>13</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Plotnik</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Hollenhorst</surname><given-names>PC</given-names></name>. <article-title>Interaction with ZMYND11 mediates opposing roles of Ras-responsive transcription factors ETS1 and ETS2</article-title>. <source>Nucleic Acids Res</source>. <year>2017</year>;<volume>45</volume>(<issue>8</issue>):<fpage>4452</fpage>&#8211;<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkx039</pub-id><pub-id pub-id-type="pmid">28119415</pub-id><pub-id pub-id-type="pmcid">PMC5416753</pub-id></mixed-citation></ref><ref id="pone.0328881.ref014"><label>14</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wei</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schaffner</surname><given-names>AE</given-names></name>, <name name-style="western"><surname>Baker</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Mansky</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Ostrowski</surname><given-names>MC</given-names></name>. <article-title>Ets-2 interacts with co-repressor BS69 to repress target gene expression</article-title>. <source>Anticancer Res</source>. <year>2003</year>;<volume>23</volume>(3A):<fpage>2173</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="pmid">12894593</pub-id></mixed-citation></ref><ref id="pone.0328881.ref015"><label>15</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Thornton</surname><given-names>CEM</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tamarapu</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Landa</surname><given-names>I</given-names></name>. <article-title>Multiple ETS Factors Participate in the Transcriptional Control of TERT Mutant Promoter in Thyroid Cancers</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>2</issue>):<fpage>357</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers14020357</pub-id><pub-id pub-id-type="pmid">35053525</pub-id><pub-id pub-id-type="pmcid">PMC8774187</pub-id></mixed-citation></ref><ref id="pone.0328881.ref016"><label>16</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Minna</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Brich</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Todoerti</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pilotti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Collini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bonaldi</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>1</issue>):<fpage>112</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers12010112</pub-id><pub-id pub-id-type="pmid">31906302</pub-id><pub-id pub-id-type="pmcid">PMC7016563</pub-id></mixed-citation></ref><ref id="pone.0328881.ref017"><label>17</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soares</surname><given-names>P</given-names></name>, <name name-style="western"><surname>P&#243;voa</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Melo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Vinagre</surname><given-names>J</given-names></name>, <name name-style="western"><surname>M&#225;ximo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Eloy</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification</article-title>. <source>Endocr Pathol</source>. <year>2021</year>;<volume>32</volume>(<issue>1</issue>):<fpage>44</fpage>&#8211;<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s12022-021-09666-1</pub-id><pub-id pub-id-type="pmid">33651322</pub-id></mixed-citation></ref><ref id="pone.0328881.ref018"><label>18</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>. <article-title>Distinct Prognostic and Immunological Roles of ETS1 and ETS2: A Pan-Cancer Analysis</article-title>. <source>Biomed Res Int</source>. <year>2023</year>;<volume>2023</volume>:<fpage>4343350</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2023/4343350</pub-id><pub-id pub-id-type="pmid">36760475</pub-id><pub-id pub-id-type="pmcid">PMC9904892</pub-id></mixed-citation></ref><ref id="pone.0328881.ref019"><label>19</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Xia</surname><given-names>L</given-names></name>. <article-title>ETS transcription factors: Multifaceted players from cancer progression to tumor immunity</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. <year>2023</year>;<volume>1878</volume>(<issue>3</issue>):<fpage>188872</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbcan.2023.188872</pub-id><pub-id pub-id-type="pmid">36841365</pub-id></mixed-citation></ref><ref id="pone.0328881.ref020"><label>20</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Exosomal miR-663b targets Ets2-repressor factor to promote proliferation and the epithelial-mesenchymal transition of bladder cancer cells</article-title>. <source>Cell Biol Int</source>. <year>2020</year>;<volume>44</volume>(<issue>4</issue>):<fpage>958</fpage>&#8211;<lpage>65</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cbin.11292</pub-id><pub-id pub-id-type="pmid">31872468</pub-id></mixed-citation></ref><ref id="pone.0328881.ref021"><label>21</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ichikawa</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Endo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Osada</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Kimura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ueki</surname><given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells</article-title>. <source>FEBS Open Bio</source>. <year>2022</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1353</fpage>&#8211;<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/2211-5463.13415</pub-id><pub-id pub-id-type="pmid">35451213</pub-id><pub-id pub-id-type="pmcid">PMC9249322</pub-id></mixed-citation></ref><ref id="pone.0328881.ref022"><label>22</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nowak</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bednarek</surname><given-names>I</given-names></name>. <article-title>Aspects of the Epigenetic Regulation of EMT Related to Cancer Metastasis</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>12</issue>):<fpage>3435</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cells10123435</pub-id><pub-id pub-id-type="pmid">34943943</pub-id><pub-id pub-id-type="pmcid">PMC8700111</pub-id></mixed-citation></ref><ref id="pone.0328881.ref023"><label>23</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Veschi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Turdo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Modica</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Verona</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Di Franco</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gaggianesi</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Recapitulating thyroid cancer histotypes through engineering embryonic stem cells</article-title>. <source>Nat Commun</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>1351</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41467-023-36922-1</pub-id><pub-id pub-id-type="pmid">36906579</pub-id><pub-id pub-id-type="pmcid">PMC10008571</pub-id></mixed-citation></ref><ref id="pone.0328881.ref024"><label>24</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Greaves</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Calle</surname><given-names>Y</given-names></name>. <article-title>Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>(<issue>4</issue>):<fpage>649</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cells11040649</pub-id><pub-id pub-id-type="pmid">35203300</pub-id><pub-id pub-id-type="pmcid">PMC8869945</pub-id></mixed-citation></ref><ref id="pone.0328881.ref025"><label>25</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Dong</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>J</given-names></name>. <article-title>Hsa_circ_0008225 inhibits tumorigenesis of glioma via sponging miR-890 and promoting ZMYND11 expression</article-title>. <source>J Pharmacol Sci</source>. <year>2020</year>;<volume>143</volume>(<issue>2</issue>):<fpage>74</fpage>&#8211;<lpage>82</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jphs.2020.02.008</pub-id><pub-id pub-id-type="pmid">32192854</pub-id></mixed-citation></ref><ref id="pone.0328881.ref026"><label>26</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>. <article-title>MicroRNA-196b promotes cell growth and metastasis of ovarian cancer by targeting ZMYND11</article-title>. <source>Minerva Med</source>. <year>2022</year>;<volume>113</volume>(<issue>4</issue>):<fpage>707</fpage>&#8211;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.23736/S0026-4806.20.06654-9</pub-id><pub-id pub-id-type="pmid">32512976</pub-id></mixed-citation></ref><ref id="pone.0328881.ref027"><label>27</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Meng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lv</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>USP53 Affects the Proliferation and Apoptosis of Breast Cancer Cells by Regulating the Ubiquitination Level of ZMYND11</article-title>. <source>Biol Proced Online</source>. <year>2024</year>;<volume>26</volume>(<issue>1</issue>):<fpage>24</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12575-024-00251-4</pub-id><pub-id pub-id-type="pmid">39044157</pub-id><pub-id pub-id-type="pmcid">PMC11264418</pub-id></mixed-citation></ref><ref id="pone.0328881.ref028"><label>28</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ren</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>M</given-names></name>. <article-title>Distinct Prognostic and Immunological Roles of ETS1 and ETS2: A Pan-Cancer Analysis</article-title>. <source>Biomed Res Int</source>. <year>2023</year>;<volume>2023</volume>:<fpage>4343350</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2023/4343350</pub-id><pub-id pub-id-type="pmid">36760475</pub-id><pub-id pub-id-type="pmcid">PMC9904892</pub-id></mixed-citation></ref><ref id="pone.0328881.ref029"><label>29</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Popova</surname><given-names>NV</given-names></name>, <name name-style="western"><surname>J&#252;cker</surname><given-names>M</given-names></name>. <article-title>The Role of mTOR Signaling as a Therapeutic Target in Cancer</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>;<volume>22</volume>(<issue>4</issue>):<fpage>1743</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms22041743</pub-id><pub-id pub-id-type="pmid">33572326</pub-id><pub-id pub-id-type="pmcid">PMC7916160</pub-id></mixed-citation></ref><ref id="pone.0328881.ref030"><label>30</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Sabatini</surname><given-names>DM</given-names></name>. <article-title>mTOR at the nexus of nutrition, growth, ageing and disease</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>183</fpage>&#8211;<lpage>203</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41580-019-0199-y</pub-id><pub-id pub-id-type="pmid">31937935</pub-id><pub-id pub-id-type="pmcid">PMC7102936</pub-id></mixed-citation></ref><ref id="pone.0328881.ref031"><label>31</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Derwich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sykutera</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bromi&#324;ska</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Andrusiewicz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rucha&#322;a</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sawicka-Gutaj</surname><given-names>N</given-names></name>. <article-title>Clinical Implications of mTOR Expression in Papillary Thyroid Cancer-A Systematic Review</article-title>. <source>Cancers (Basel)</source>. <year>2023</year>;<volume>15</volume>(<issue>6</issue>):<fpage>1665</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/cancers15061665</pub-id><pub-id pub-id-type="pmid">36980552</pub-id><pub-id pub-id-type="pmcid">PMC10046096</pub-id></mixed-citation></ref><ref id="pone.0328881.ref032"><label>32</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lv</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>F-K</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>Z-P</given-names></name>, <name name-style="western"><surname>Jia</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>P-J</given-names></name>, <etal>et al</etal>. <article-title>M2&#8209;like tumour&#8209;associated macrophage&#8209;secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K/AKT/mTOR pathway</article-title>. <source>Mol Med Rep</source>. <year>2021</year>;<volume>24</volume>(<issue>2</issue>):<fpage>604</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3892/mmr.2021.12249</pub-id><pub-id pub-id-type="pmid">34184083</pub-id><pub-id pub-id-type="pmcid">PMC8258465</pub-id></mixed-citation></ref><ref id="pone.0328881.ref033"><label>33</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maracci</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Motta</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Romagnoli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Costantino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Perego</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Di Marino</surname><given-names>D</given-names></name>. <article-title>The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets</article-title>. <source>Curr Med Chem</source>. <year>2022</year>;<volume>29</volume>(<issue>20</issue>):<fpage>3501</fpage>&#8211;<lpage>29</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2174/0929867329666220224112042</pub-id><pub-id pub-id-type="pmid">35209811</pub-id></mixed-citation></ref><ref id="pone.0328881.ref034"><label>34</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name>. <article-title>ZSCAN16 promotes proliferation, migration and invasion of bladder cancer via regulating NF-kB, AKT, mTOR, P38 and other genes</article-title>. <source>Biomed Pharmacother</source>. <year>2020</year>;<volume>126</volume>:<fpage>110066</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110066</pub-id><pub-id pub-id-type="pmid">32172065</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>